Following the release of the medication lots by the U.S. Food anAdditional Data Highlight PALISADE Study Patient Baseline Characteristics and Associated Treatment Response — and Improvements in Self-Reported Quality of Life Following Long-Term Treatment with PALFORZIAAimmune Therapeutics, Inc. (Nasdaq: AIMT), today announced financial results for the fourth quarter and full year 2019.© 1985 - 2020 BioSpace.com. Of this latter group, percentages are higher in younger age groups; 35% in children and 42% in teenagers, compared with 26% in adults.

Learn more about our company and explore current openings. - Nearly half of all respondents (n=1,846) (46%) describe living with the disease as “more” or “much more” expensive than living without the disease, pointing to a financial burden associated with managing peanut allergy. Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T. BRISBANE, Calif.--( BUSINESS WIRE )-- “The study provides essential insight and data on peanut allergy comorbidities, severity of reactions, management, and suggests a widespread need in Europe for improved quality of peanut allergy health management and education”, said Daniel Adelman, Chief Medical Officer of Aimmune. The ARTEMIS trial enrolled 175 peanut-allergic children and adolescents ages 4 to 17 from 18 sites in Peanut allergy is one of the most common food allergies, which affects over 17 million people in Europe. Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference.

To access the live call by phone, dial (877) 497-1Aimmune Therapeutics to Present at the 19 th Annual Needham Virtual Healthcare Conference

The findings illustrate the impact of living with the condition, and how attempting to avoid peanuts every day can be a major source of stress, fear and anxiety, clouded by the persistent worry of accidental exposure for both the allergic individual and their caregiver. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational highlights. P/0114/2019: EMA decision of 29 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for peanut flour (EMEA-001734-PIP01-14-M04) (PDF/184.03 KB) Adopted First published: 24/06/2019 … Here’s a look. Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode 6195241.

Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the risk that the COVID-19 worldwide pandemic may continue to negatively impact the business, research and clinical operations of Aimmune or its partners; Aimmune’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune’s or any of its collaborative partners’ clinical trials will not be successful; Aimmune’s dependence on the success of commercialization; Aimmune’s reliance on third parties for the manufacture of Aimmune’s products and product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune’s ability to attract and retain senior management personnel These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.